Technology Insight: Imaging neurodegeneration in Parkinson's disease

Nature Clinical Practice Neurology

Volumn 4, Issue 5, 2008, Pages 267-277

  Brooks, David J ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b GE HEALTHCARE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; DIHYDROTETRABENAZINE; FLUORODEOXYGLUCOSE F 18; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE;

BRAIN METABOLISM; DEMENTIA; DEPRESSION; DIAGNOSTIC ACCURACY; DIFFUSE LEWY BODY DISEASE; DIFFUSION WEIGHTED IMAGING; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; NERVE DEGENERATION; NEUROIMAGING; PARASOMNIA; PARKINSON DISEASE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREMOR; VOLUMETRY;

DIAGNOSTIC IMAGING; HUMANS; NERVE DEGENERATION; PARKINSON DISEASE;

EID: 43149103142     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0773     Document Type: Review

References (70)

1. Hughes AJ et al. (1992) What features improve the accuracy of clinical diagnosis in Parkinson's disease: A clinicopathological study. Neurology 42: 1142-1146
2. Fearnley JM and Lees AJ (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114: 2283-2301
3. Hughes AJ et al. (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181-184
4. Berg D et al. (2001) Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol 248: 684-689
5. Berg D et al. (2005) Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov Disord 20: 383-385
6. Berg D et al. (2002) Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59: 999-1005
7. Hutchinson M and Raff U (2000) Structural changes of the substantia nigra in Parkinson's disease as revealed by MR imaging. AJNR Am J Neuroradiol 21: 697-701
8. 18F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease. Neurology 56: 1195-1200
9. Minati L et al. (2007) Imaging degeneration of the substantia nigra in Parkinson disease with inversion-recovery MR imaging. AJNR Am J Neuroradiol 28: 309-313
10. Michaeli S et al. (2007) Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. Mov Disord 22: 334-340
11. Geng DY et al. (2006) Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson's disease. Neurosurgery 58: 256-262
12. Schulz JB et al. (1999) Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol 45: 65-74
13. Paviour DC et al. (2006) Regional brain volumes distinguish PSP, MSA-P, and PD: MRI-based clinico-radiological correlations. Mov Disord 21: 989-996
14. Seppi K et al. (2003) Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 60: 922-927
15. Nicoletti G et al. (2006) Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Brain 129: 2679-2687
16. Paviour DC et al. (2007) Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple-system atrophy from progressive supranuclear palsy. Mov Disord 22: 68-74
17. Brooks DJ et al. (2003) Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 184: S68-S79
18. 18F] dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 59: 597-600
19. 123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease. Brain 129: 1188-1193
20. Whone AL et al. (2003) Plasticity in the nigropallidal pathway in Parkinson's disease: An 18F-dopa PET study. Ann Neurol 53: 206-213
21. 123I]-FP-CIT Study Group. Mov Disord 15: 503-510.
22. 123I-ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 19: 1175-1182
23. 123I) β-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: Unmasking an early diagnosis. Arch Neurol 61: 1224-1229
24. 123I)FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with ather forms of parkinsonism. Eur J Nucl Med 28: 266-272
25. Scherfler C et al. (2007) Role of DAT-SPECT in the diagnostic work up of Parkinsonism. Mov Disord 22: 1229-1238.
26. Marshall VL at al. (2006) Two-year follow-up in 150 consecutive cases with formal dopamine transporter imaging. Nucl Med Commun 27: 933-937
27. Brooks DJ (1993) Functional imaging in relation to parkinsonian syndromes. J Neurol Sci 115: 1-17
28. Eidelberg D et al. (1994) The metabolic topography of parkinsonism. J Cerab Blood Flow Metab 14: 783-801
29. Su PC et al. (2001) Metabolic changes following subthalamotomy for advanced Parkinson's disease. Ann Neurol 50: 514-520
30. Feigin A et al. (2001) Metabolic correlates of levodopa response in Parkinson's disease. Neurology 57: 2083-2088
31. Eckert T et al. (2007) Regional metabolic changes in parkinsonian patients with normal dopaminergic imaging. Mov Disord 22 167-173
32. 18F-dopa PET data. J Neurol Neurosurg Psychiatry 57: 278-284
33. 123I]β-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 15: 1158-1167
34. Eckert T et al. (2005) FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 26: 912-921
35. 18F-dopa PET study. Neurobiol Dis [doi:10.1016/j.nbd.2007.09.004]
36. 11C-WAY 100635 PET study. Neurology 60: 601-605
37. 123I-p-CIT SPECT. J Nucl Med 44: 870-876
38. Remy P et al. (2005) Depression in Parkinson's disease: Loss of dopamine and noradrenaline innervation in the limbic system. Brain 128: 1314-1322
39. Kuhl DE et al. (1996) In vivo mapping at cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 40: 399-410
40. Hilker R et al. (2005) Dementia in Parkinson's disease: Functional imaging of cholinergic and dopaminergic pathways. Neurology 65 1716-1722
41. Bohnen NI et al. (2003) Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: An in vivo positron emission tomographic study. Arch Neurol 60: 1745-1748
42. Bohnen NI et al. (2005) Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease. Neurosci Lett 380 127-132
43. Golbe LI (1990) The genetics of Parkinson's disease: A reconsideration. Neurology 40 (Suppl 3): S7-S16
44. Berg D et al. (2001) Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology 56: 13-17
45. Walter U et al. (2004) Brain parenchyma sonography detects preclinical parkinsonism. Mov Disord 19: 1445-1449
46. Sommer U et al. (2004) Detection of presymptomatic Parkinson's disease: Combining smell tests, transcranial sonography, and SPECT. Mov Disord 19: 1196-1202
47. Ponsen MM et al. (2004) Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 56: 173-181
48. 18F-dopa PET study. Ann Neurol 41: 222-229
49. Hilker R et al. (2002) The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: Evidence for enzymatic parkin function in htknans. Neurosci Lett 323: 50-54
50. 18F]dopa PET and clinical study. Brain 125: 2248-2256
51. Scherfler C et al. (2004) Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain 127: 1332-1342
52. Khan NL et al. (2005) Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology 64: 134-136
53. Adams JR et al. (2005) PET in LRRK2 mutations: Comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 128: 2777-2785
54. Stiasny-Kolster K et al. (2005) Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for α-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 128: 126-137
55. Imamura K et al. (2003) Distribution of major histocompatibility complex class II-positive microglia. and cytokine profile of Parkinson's disease brains. Acta Neuropathol 106: 518-526
56. Ouchi Y et al. (2005) Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 57: 168-175
57. 11C(R)-PK11195 PET study. Neurology 62 (Suppl 5): A432
58. Braak H et al. (2004) Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318: 121-134
59. Summerfield C et al. (2005) Structural brain changes in Parkinson disease with dementia: A voxel-based morphometry study. Arch Neurol 62: 281-285
60. Ramirez-Ruiz B et al. (2005) Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia. J Neurol 252: 1345-1352
61. Burton EJ et al. (2005) Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging. Mov Disord 20: 1571-1576
62. Bohnen NI et al. (1999) Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia. Neurology 52: 541-546
63. 18FDG-PET study. Brain 123: 340-352
64. Klunk WE et al. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55: 306-319
65. Edison P et al. (2007) Amyloid load in Lewy body dementia (LBD), Parkinson's disease dementia (PDD) and Parkinson's disease (PD) measured with C-11-PIB PET. Neurology 68: A98
66. Walker Z et al. (2007) Dementia with Lewy bodies: A comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 78: 1176-1181
67. Walker Z et al. (2002) Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergric presynaptic ligand. J Neurol Neurosurg Psychiatry 73: 134-140
68. Walker Z et al. (2004) Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: A comparison. Neurology 62: 1568-1572
69. 18F]fluoro-L-dopa PET study. Brain 125: 1358-1365
70. 18F]fluorodopa positron emission tomographic study. Arch Neurol 57: 470-475.